Clinical Trial

Pilot Bioequivalence Study of Chiglitazar/Metformin Extended-Release Tablets

Not Yet Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated February 17, 2026 (before its estimated June 29, 2026 completion). Its status may not reflect the trial's current state.
Summary
This is a pilot bioequivalence study. It is a randomized, open-label, single-dose, crossover study. The primary objective of this study is to preliminarily evaluate the pharmacokinetic parameters and their variability of the test formulation versus the reference formulation following a single oral dose under fed conditions.
Trial Details
NCT Number NCT07412015
Lead Sponsor Chipscreen Biosciences, Ltd.
Conditions T2DM (Type 2 Diabetes Mellitus)
Enrollment 24 participants
Start Date 2026-05-27
Primary Completion 2026-06-29 (estimated)
Study Completion 2026-06-29 (estimated)
Updated on ClinicalTrials.gov 2026-02-17